Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality

• Main Authors: Andreas Pircher, Dominik Wolf, Axel Heidenreich, Wolfgang Hilbe, Renate Pichler, Isabel Heidegger
• Format: Article
• Language: English
• Published: MDPI AG 2017-10-01
• Series: International Journal of Molecular Sciences
• Subjects: angiogenesis; immunotherapy; checkpoint inhibition; VEGF inhibition; renal cell cancer; non-small cell lung cancer
• Online Access: https://www.mdpi.com/1422-0067/18/11/2291

In recent years, considerable advances concerning therapeutic strategies in patients with metastatic cancer have been achieved. Particularly in renal cell cancer (RCC) and advanced stage non-small cell lung cancer (NSCLC), immune-activating and antiangiogenic (AA) drugs (i.e., checkpoint antibodies and vascular endothelial growth factor (VEGF)/VEGF receptors (VEGFR) targeting compounds, respectively) have been successfully developed. As immune-effector cells have to enter the tumor, it is tempting to speculate that the combination of immunotherapy with AA treatment may induce synergistic effects. In this short review, we explore the theoretical background and the therapeutic potential of this novel treatment option for patients with advanced RCC or NSCLC. We discuss the growing body of evidence that pro-angiogenic factors negatively modulate the T-cell-mediated immune response and examine the preclinical evidence for testing combined immune-activating and AA therapy concepts in clinical practice. Particular attention will also be paid to potential novel treatment-related adverse events induced by combination treatment.